to be studied in their native genetic background, but is often hampered by limited access to traditional disease-related cell types (such as pancreatic cells for diabetes). In genetically tractable model organisms, genetic interaction screens provide a powerful, systematic method to reveal genes and pathways that interact with a given mutation (1-3); similarly, in genetically defined cell lines, the concept of synthetic lethality has been used to identify compounds that selectively kill cells expressing an oncogene (4) .
Here, we apply the logic of genetic interaction screens to study human disease alleles in cells from individual patients, using small-molecule probes as a source of systematic perturbation (particularly marketed drugs and bioactives with characterized activity). To discover small molecule-gene interactions, we screen for small molecules that induce distinct cellular phenotypes depending on the presence or absence of a disease mutation (Fig. 1 
RESULTS

Small molecule-disease allele interaction screen in patient LCLs
We studied LCLs from 18 members of a MODY1 family (10 with diabetes and 8 without; Fig. 2 ) in which affected members possess a Q268X nonsense mutation (16) . This mutation truncates the ligand binding domain and leads to impaired DNA binding, abnormal cellular trafficking, and loss of transcriptional activity (8, 17) . Sequencing and RT-PCR confirmed the presence of a heterozygous C-to-T substitution in codon 268 exclusively in the diabetic subjects, and low levels of HNF4 expression. LCLs were treated with 3,973 clinically used drugs and small molecules whose activities have been previously characterized. The effects of small-molecule treatments were measured using a luminescence assay for cellular ATP content, chosen as a viability assay, and also for reasons related to diabetic metabolism: type-2 diabetes has been associated with impairments in oxidative phosphorylation (18) , and ATP concentrations in pancreatic islets are a key sensor during insulin secretion (19) . ATP assay values were converted to a Z-score (multiples of the standard deviation of the distribution of control wells in the same cell line) (20) . The assay was highly reproducible with a coefficient of variation routinely <10% (Supplemental Table S1 ). Each small-molecule treatment was performed in duplicate at a single concentration. 
Compound-set-enrichment-analysis identifies small molecules with disease-allele dependent effects
While many small molecules with the most positive or most negative S2N had p values < 0.05 (calculated by permutation of mutant and wild-type class labels;
Supplemental Dataset S1), after correcting for multiple hypothesis testing, individual compounds did not meet statistical significance. To better identify patterns in these data, we tested whether sets of related compounds were statistically enriched among the most discriminating compounds, even if the discriminating effect of individual compounds was subtle. We curated the screened compounds into 141 compound sets (each containing from 3 to 60 compounds) based on drug class or activity in a common biologic pathway (Supplemental Table S2 ). A weighted Kolmogorov-Smirnov-like statistic (normalized enrichment score, NES) was calculated for each compound set that reflects the extent to which set members are statistically enriched among compounds with the most positive or negative S2N; P-values were calculated by randomly permuting mutant vs. wild-type class labels 1000 times (Figures 4a and   4b ). This approach is analytically analogous to gene set enrichment analysis (18, 22) for gene expression data, and has been used to robustly identify groups of genes (e.g., related by virtue of belonging to a common biological process or pathway) that are differentially expressed in two cell types.
The most highly ranked compound sets from this approach are listed in Table 1 (compound set members are listed in Supplemental Table S3 ). These include several classes of drugs approved for conditions other than diabetes, as well as a subtype of fatty acids (Fig. 4b ). Of note, these compound sets scored narrowly better than a set comprised of the most widely used therapy for MODY1, the insulin secretagogues belonging to the sulfonylurea class (such as glimepiride and tolbutamide; NES = 1.27). We verified that previously reported confounders of small-molecule treatment in LCLs such as LCL growth rate and EBV copy number (23) do not differ in mutant vs. wild-type LCLs (p = 0.59 and 0.26, respectively) (Supplemental Fig. S1 ). We also confirmed that the observed variation in small-molecule-induced ATP measurements did not correlate with the growth rate of individual LCLs (Supplemental Fig. S2 ).
A significant fraction of small molecule-gene interactions are preserved from LCLs to pancreatic β cells
Representative members of the compound sets in Table 1 Representative individual compounds from compound sets in Table 1 were confirmed to induce distinct responses in mutant vs. wild-type LCLs (Supplemental Fig. S3 ). In pancreatic cells, 4/9 of the representative compounds induced distinct ATP measurements in HNF4 knockdown vs.
control cells (Table 1 ; Fig. 5 shows results for these 4 compounds, as well as for dexamethasone, a glucocorticoid that did not show an interaction with HNF4 in cells). These include the -6 fatty acid linoleic acid, and several FDA-approved drugs: amiloride (a potassium-sparing diuretic that inhibits the epithelial sodium channel); propafenone (an anti-arrhythmic drug that inhibits sodium channels as well as other ion channels); and simvastatin (an HMG CoA-reductase inhibitor used to treat hyperlipidemia) (Fig. 5 ). These experiments demonstrate that a significant portion of small molecule-gene interactions that are elucidated in individual patient LCLs are also preserved in pancreatic cells, a canonical cell model for diabetes.
Small molecules that functionally interact with HNF4α modulate insulin secretion
Small molecules that emerge from the screen or their protein targets presumably participate in the same or related biological processes as those involving HNF4 .
We hypothesized that some of these proteins (and their associated pathways) may help mediate the cellular effects of disease mutations in HNF4 , and that modulation of these proteins may favorably modify disease phenotypes. Because MODY1 patients display impaired insulin secretion (24), we tested the small molecules identified in our screen for their effects on insulin secretion from pancreatic cells. Several compounds that showed an interaction with HNF4 status in cells also modulated insulin secretion, and compounds from different classes exerted distinct patterns of effect ( Fig. 6 ; Supplemental Table S4 ). In cells wild-type for HNF4 , linoleic acid, amiloride, propafenone and simvastatin all increased insulin secretion at basal glucose concentrations (2.5 mM); linoleic acid and propafenone also increased insulin secretion at elevated glucose (12.5 mM). Notably, in HNF4 knockdown cells, linoleic acid, propafenone, and amiloride also increased insulin secretion in the presence of low glucose, high glucose, or both, respectively; at high glucose concentration, amiloride and propafenone restored insulin secretion in HNF4 knockdown cells to wild-type levels (Fig. 6 ). Simvastatin caused a complex phenotype, stimulating insulin secretion at 2.5 mM glucose but inhibiting insulin secretion at 12.5 mM glucose.
The distinct effects these compounds exert on insulin secretion (e.g., as a function of glucose concentration and mutation status; Supplemental Table S4) likely reflect both the complexity of insulin secretion physiology and the different mechanisms of different compounds. Overall, these data illustrate that small molecule-disease allele interactions can identify compounds that modulate disease-modifying pathways, and exert therapeutically beneficial or adverse effects on disease phenotypes.
DISCUSSION
By studying blood-derived cells from individuals, we have identified novel connections between HNF4α, several drugs, cellular ATP, and insulin secretion.
These connections add a functional framework to the existing vast catalog of HNF4α transcriptional targets, and suggest several new mechanistic and therapeutic hypotheses. None of the drugs identified in our study have been studied in association with MODY1, and none were approved for diabetes-related indications.
One of the compounds identified in our screen, linoleic acid, was the predominant species bound to HNF4 (based upon gas chromatography/mass spectrometry (GC/MS)) in livers from fed mice or when rat HNF4 was expressed in human cells (25) . Furthermore, crystal structures of HNF4 show a mixture of fatty acids spontaneously bound to the ligand-binding pocket (26, 27) .
These reports suggest that the emergence of linoleic acid and related fatty acids from our screen likely arises from their physical association with HNF4 , which strongly supports the ability of our method to identify physiologically relevant This approach can therefore be particularly useful to study disease alleles that are not easily studied by traditional genetic methods. By using small molecules as a source of targeted perturbations in patient-derived cells, the approach brings the logic of model organism genetics to genetically complex human diseases.
Chemical-genetic interaction screens in patient samples can help discover proteins that participate in disease-relevant processes (thus placing the disease mutation in a biological context), and equally important, identify small molecules, FDA-approved drugs or genes that act as disease modifiers. Biological discovery and clinical translation may be accelerated since a small molecule can be used both to elicit the interaction with the disease mutation and to ameliorate disease phenotypes. Small-molecule-based genetic interaction screens using patientderived blood cells are useful for exploring a highly heritable form of diabetes, and may prove useful for functional studies and clinical translation of human disease susceptibility alleles discovered through genome-wide association and other genetic studies.
METHODS
Lymphoblast cell line (LCL) culture, small molecule screen, and ATP assay
LCLs were purchased from Coriell Cell Repositories (Camden, NJ; Figure 2) , and cultured and maintained as previously described (23) . For screening, LCLs were thawed from frozen stocks and maintained by diluting them to 100,000-300,000 cells/ml daily for ~20 days prior to screening. LCLs were plated in 40 µl media at a density of 300,000 cells/ml. 100 nl was then pin transferred from compound libraries using a CyBi-Well Vario robot (CyBio US, Boston, MA) and plates were incubated at 37°C and 5% CO 2 for 40 hours. The CellTiter-Glo (Promega Corp.,
Madison, WI)) assay for cellular ATP was performed as described (23) 
Analysis of interaction screen
Replicate raw luminescence values for each compound library member in each cell line were converted to a Z-score using a standard analytic pipeline (20) .
Calculation of signal-to-noise score (S2N) for each compound across all LCL lines, and rank-ordering of compounds for their ability to discriminate LCLs that are mutant vs. wild-type at HNF4α was performed using the Comparative Marker Selection module of GenePattern (41, 42) , a data analysis platform for genomics and other systematically acquired data sets (http://www.broadinstitute.org/cancer/software/genepattern/); we used compound Z-scores instead of gene expression values as inputs, and otherwise standard settings. P-values were determined by randomly permuting mutant and wild-type class labels. For compound set enrichment analysis, we manually curated our screened compound list into 141 compound sets of at least 3 compounds (Supplemental Table S2 for all 141 set names; individual compounds making up the top scoring sets are listed in Supplemental Table S3 ). We used the GSEA (Gene Set Enrichment Analysis) module of GenePattern, which calculates a weighted Kolmogorov-Smirnov-like statistic (normalized enrichment score, NES)
for each compound set; this score reflects the extent to which set members cause statistically significant, concordant differences in ATP Z-scores between mutant vs. wild-type (at HNF4α) LCLs (18, 22) . 
Statistical analysis
When comparing the assay results of two different cell populations (e.g., individual compound treatments of mutant vs. wild-type LCLs, or of HNF4α-vs.
control-knockdown β cells), the two-sided, unpaired Student's t-test was used.
For compound-set-enrichment-analysis, p-values for enrichment scores were calculated by randomly permuting wild-type vs. mutant class labels for the LCLs 1000 times (see "Analysis of interaction screen" section of Methods for details).
Two-way ANOVAs were performed to examine the effect of compound treatment and HNF4α mutation status on insulin secretion assays. Table S2 ). Representative compounds from each set were tested for their ability to also discriminate between controland HNF4α-knockdown β cells (last column and Fig. 5 ).
